Alexion switches to solar power
This article was originally published in Scrip
Alexion Pharmaceuticals has strengthened its green credentials by putting solar panels generating 295kW on the rooftop of its facility in Cheshire, Connecticut, which will provide 9% of its electrical needs. The system was funded by a grant from the Connecticut Clean Energy Fund. The 1,738 photovoltaic cells will reduce its carbon dioxide emissions by 380,000 lbs annually, the company estimates. Alexion markets the appropriately named product Soliris (eculizumab), for the rare and life-threatening blood disorder, paroxysmal nocturnal haemoglobinuria.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
Although top-line efficacy results from a small study in critically ill patients with COVID-19 suggest there are therapeutic benefits associated with Relief Therapeutics/NeuroRx’s RLF-100 (aviptadil), further data are awaited from the results of a randomized clinical trial, expected later this year.